Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SUPN files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSupernus reports 39% Q1 revenue growth to $207.7M, driven by ZURZUVAE and ONAPGO
Filed May 5, 2026 · Period ending May 5, 2026 · ~1 min read
Key Changes
-
high
Q1 2026 revenues rose 39% year-over-year to $207.7M, driven by 56% growth in four key products (Qelbree, GOCOVRI, ZURZUVAE, ONAPGO) to $149.1M and a $20M Shionogi commercial milestone.
Item 2.02 — Results of Operations and Financial Condition verify on EDGAR → -
high
ZURZUVAE collaboration revenue reached $27.6M (50% of Biogen's net revenues); Biogen reported U.S. sales doubled year-over-year and total prescriptions increased 82%.
Exhibit 99.1 view on EDGAR → -
high
Company reaffirmed full-year 2026 guidance: $840-870M total revenues, $0-30M operating earnings, and $140-170M adjusted operating earnings.
Exhibit 99.1 view on EDGAR → -
medium
ONAPGO generated $8.4M in Q1 sales after resuming new patient starts in February; company plans Q3 2026 FDA filing for second supplier with potential mid-2027 approval to address supply constraints.
Exhibit 99.1 view on EDGAR → -
medium
Shionogi collaboration delivered a one-time $20M commercial milestone, contributing to 274% increase in royalty and licensing revenues to $29.3M.
Exhibit 99.1 view on EDGAR →
Summary
Supernus delivered strong first-quarter results with 39% revenue growth to $207.7 million, demonstrating momentum across its growth portfolio. The standout performer was ZURZUVAE, the postpartum depression treatment co-marketed with Biogen, which doubled U.S. sales year-over-year and contributed $27.6 million in collaboration revenue to Supernus.
ONAPGO, the company's Parkinson's disease psychosis treatment, resumed new patient initiations in February after supply constraints and generated $8.4 million in Q1 sales, with over 645 prescribers submitting enrollment forms since launch. The quarter also included a $20 million one-time commercial milestone from Shionogi, boosting licensing revenues.
Operating losses narrowed to $8.3 million from $10.3 million a year earlier. Management reaffirmed full-year 2026 guidance of $840-870 million in revenues and $140-170 million in adjusted operating earnings, signaling confidence in the growth trajectory. The planned Q3 2026 FDA filing for a second ONAPGO supplier addresses a key operational risk, with potential approval by mid-2027 to support expanded patient access.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Supernus announced Q1 2026 financial results via press release and conference call on May 5, 2026.
Added in current filing · verify on EDGAR →
On May 5, 2026, Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) issued a press release regarding its financial results for the first quarter ended March 31, 2026.
The company disclosed its first quarter 2026 financial results through a press release. The 8-K itself does not contain the actual financial figures — those are in the attached press release exhibit. The company also hosted a conference call on the same day to present business and financial results.
Event · Exhibit 99.1
Added in current filing · view on EDGAR →
Total revenues were $207.7 million in the first quarter 2026, a 39% increase compared to same period last year.
Supernus reported total revenues of $207.7 million for Q1 2026, up 39% year-over-year from $149.8 million. The growth was driven by a 56% increase in combined revenues from four growth products (Qelbree, GOCOVRI, ZURZUVAE, ONAPGO) to $149.1 million, plus a $20 million commercial milestone from Shionogi. Operating loss narrowed to $8.3 million from $10.3 million in Q1 2025.
Added in current filing · view on EDGAR →
Regulatory submission to the FDA for second supplier for ONAPGO expected in third quarter 2026, with potential approval by mid-year 2027.
Supernus plans to file a regulatory submission to the FDA for a second supplier for ONAPGO in Q3 2026, with potential approval by mid-2027. This addresses supply constraints that paused new patient initiations; ONAPGO resumed new patient starts in February 2026 and generated $8.4 million in Q1 2026 net sales. Approximately 2,200 enrollment forms have been submitted by over 645 prescribers since the April 2025 launch.
Added in current filing · view on EDGAR →
For the full year 2026, the Company reiterates its full year financial guidance as set forth below (dollars in millions): Current Guidance (as of February 24, 2026) Total revenues include the following(7): ◦ONAPGO net sales of $45 million - $70 million ◦Trokendi XR and Oxtellar XR net sales of $40 - $50 million $840 - $870 Combined R&D and SG&A expenses $620 - $650 Operating earnings $0 - $30 Adjusted operating earnings (non-GAAP) (1) $140 - $170
Supernus reiterated its full-year 2026 guidance: total revenues of $840-870 million (including ONAPGO net sales of $45-70 million and Trokendi XR/Oxtellar XR net sales of $40-50 million), combined R&D and SG&A expenses of $620-650 million, operating earnings of $0-30 million, and adjusted operating earnings (non-GAAP) of $140-170 million.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 19, 2026 · How we verify